LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

LLY

1,072.47

+0.53%↑

JNJ

230.78

-1.62%↓

ABBV

212.58

-1.64%↓

UNH

379.52

-2.23%↓

AZN

187.27

+0.01%↑

Kodu・Aktsiate loetelu・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Avatud

SektorTervishoid

18.45 -0.75

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.13

Max

18.56

Põhinäitajad
By Trading Economics
Sissetulek	-607K -51M
Müük	-28M 100M
Aktsiakasum	-0.46
Kasumimarginaal	-51.215
Töötajad	1,784
EBITDA	4.1M -44M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+74.1% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. aug 2026

Turustatistika
By TradingEconomics
Turukapital	-294M 2.1B
Eelmine avamishind	19.2
Eelmine sulgemishind	18.45

Uudiste sentiment

By Acuity

30%

70%

80 / 345 Pingereas Healthcare

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. mai 2026, 08:24 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25. mai 2026, 21:22 UTC

Tulu

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25. mai 2026, 20:50 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:20 UTC

Market Talk

Tulu

Basic Materials Roundup: Market Talk

25. mai 2026, 16:01 UTC

Market Talk

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25. mai 2026, 14:43 UTC

Market Talk

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25. mai 2026, 14:15 UTC

Market Talk

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25. mai 2026, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25. mai 2026, 12:58 UTC

Market Talk

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25. mai 2026, 12:56 UTC

Market Talk

Tulu

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25. mai 2026, 12:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. mai 2026, 12:34 UTC

Market Talk

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25. mai 2026, 12:10 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero's Assets Look Strategic -- Market Talk

25. mai 2026, 11:00 UTC

Market Talk

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25. mai 2026, 10:19 UTC

Market Talk

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25. mai 2026, 10:05 UTC

Tulu

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25. mai 2026, 10:04 UTC

Tulu

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25. mai 2026, 10:03 UTC

Tulu

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25. mai 2026, 10:02 UTC

Tulu

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25. mai 2026, 10:01 UTC

Tulu

Tenaga Nasional 1Q Net Up 3.7% on Year

25. mai 2026, 10:00 UTC

Tulu

Tenaga Nasional 1Q Rev Up 6.6% on Year

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q EPS MYR0.1883

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Rev MYR17.1B

25. mai 2026, 09:56 UTC

Tulu

Tenaga Nasional 1Q Net MYR1.1B

25. mai 2026, 09:38 UTC

Market Talk

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25. mai 2026, 09:33 UTC

Market Talk

Global Equities Roundup: Market Talk

25. mai 2026, 09:33 UTC

Market Talk

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25. mai 2026, 08:55 UTC

Market Talk

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

74.1% tõus

12 kuu keskmine prognoos

Keskmine 32.4 USD 74.1%

Kõrge 44 USD

Madal 21.6 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Zai Lab Ltd ADR aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

80 / 345 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.